Free Trial
NASDAQ:OCS

Oculis Q1 2025 Earnings Report

Oculis logo
$17.61 -0.03 (-0.17%)
As of 08/1/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.77
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.26
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
$0.32 million
Expected Revenue
$0.22 million
Beat/Miss
Beat by +$100.00 thousand
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Oculis' Q2 2025 earnings is scheduled for Tuesday, August 26, 2025, with a conference call scheduled on Thursday, August 21, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Oculis Earnings Headlines

Oculis Upsized Loan Facility to Access up to CHF 100 million
The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Oculis Upsized Loan Facility to Access up to CHF 100 million
OCS - Oculis Holding AG Executives - Morningstar
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat